SCHEMBL30765478

SCHEMBL30765478

O=C(Cn1c(-c2ccccc2)ncc(NC(=O)c2cccc(-c3ncco3)c2)c1=O)NCc1cc2cnccc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 1/20 0.41
NTRK1 P04629 6/20 0.39
NTRK3 Q16288 4/20 0.39
ELANE P08246 5/20 0.38
CMA1 P23946 3/20 0.36
CTRC Q99895 2/20 0.36
HDAC1 Q13547 1/20 0.36
F3 P13726 1/20 0.35
MAPK8 P45983 1/20 0.35
MAPK9 P45984 1/20 0.35
MAPK10 P53779 1/20 0.35
F2 P00734 1/20 0.35
TRPM4 Q8TD43 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31558568 0.87 NTRK1 (0.45) CASP1NTRK1NTRK3ELANECMA1
SCHEMBL30765488 0.86 NTRK1 (0.46) CASP1NTRK1NTRK3ELANECMA1
SCHEMBL30765954 0.84 HDAC1 (0.40) CASP1NTRK1NTRK3ELANECMA1
SCHEMBL30765974 0.83 CASP1 (0.44) CASP1NTRK1NTRK3ELANECMA1
SCHEMBL30765889 0.83 ELANE (0.38) CASP1NTRK1NTRK3ELANECMA1
SCHEMBL30765732 0.83 NTRK1 (0.40) CASP1NTRK1NTRK3ELANECMA1
SCHEMBL30766050 0.83 ELANE (0.41) CASP1NTRK1NTRK3ELANECMA1
SCHEMBL30765443 0.82 ELANE (0.39) CASP1NTRK1NTRK3ELANECMA1
SCHEMBL30765851 0.82 NTRK1 (0.40) CASP1NTRK1NTRK3ELANECMA1
SCHEMBL30765557 0.82 CASP1 (0.46) CASP1NTRK1ELANETRPM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed